Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2+ Breast Cancer
NCT00542451Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2007
- Primary completion
- Apr 2014
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and paclitaxel in breast cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Disease-Free Survival at 3 years. Started Oct 2007; status: completed.
02
Drugs
trastuzumabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00542451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542451.